Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03030261 · ClinicalTrials.gov registry record · Phase 2

Elotuzumab, Pomalidomide, & Dexamethasone (Elo-Pom-Dex) With Second Autologous Stem Cell Transplantation for Relapsed Multiple Myeloma

A Phase 2 study of Multiple Myeloma in Relapse, sponsored by Washington University School of Medicine.

Active
Registry status
Phase 2
Development phase
25
Enrollment target
3
Study locations

NCT03030261 is a Phase 2 study of Multiple Myeloma in Relapse that is active but no longer recruiting, run by Washington University School of Medicine. The registered enrollment target is 25 participants, below the 50-participant average among 12 other Multiple Myeloma in Relapse trials with a reported enrollment target (50% lower). The trial reports 3 study locations across 3 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03030261, a Phase 2 study of Multiple Myeloma in Relapse, is active but no longer recruiting, sponsored by Washington University School of Medicine.

ACTIVE NOT RECRUITING
Registry status
Phase 2
Development phase
25 participants
Enrollment target
3
Study locations

Study Summary

Based on the need to improve outcomes post second autologous stem cell transplant (ASCT) for multiple myeloma (MM) and the benefits seen of maintenance treatment following initial ASCT, the natural next step is to evaluate maintenance/continuation therapy following second ASCT. Pomalidomide is active against MM cells refractory to both bortezomib and lenalidomide, making it an ideal choice for continuation therapy following second ASCT. Adding elotuzumab may increase efficacy and also the durability of responses which is essential to improving outcomes following second ASCT.

Conditions Studied

Multiple Myeloma in Relapse

Interventions

  • DRUG Dexamethasone
  • DRUG Pomalidomide
  • DRUG Elotuzumab

Study Locations (3)

Colorado

  • Colorado Blood Cancer Institute (Sarah Cannon) - Denver

Missouri

  • Washington University School of Medicine - St Louis

Ontario

  • University Health Network - Princess Margaret Cancer Centre - Toronto

Trial Details

FieldValue
Enrollment Target 25 participants
Start Date 2017-11-22
Est. Completion 2027-09-26
Phase Phase 2

Sponsor

Washington University School of Medicine

1,502 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT03030261

The ClinicalTrials.gov registry entry for NCT03030261 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 50-participant average among 12 other Multiple Myeloma in Relapse trials with a reported enrollment target (50% lower). The listed sponsor is Washington University School of Medicine, which has 1,502 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Multiple Myeloma in Relapse appearing as the primary indexed condition, and to 3 interventions - of which Dexamethasone is the first listed.

NCT03030261 reports 3 study locations spanning 3 distinct geographic areas - top geographies include Colorado, Missouri, Ontario.

Frequently Asked Questions

What is clinical trial NCT03030261 about?

NCT03030261 is a clinical study titled "Elotuzumab, Pomalidomide, & Dexamethasone (Elo-Pom-Dex) With Second Autologous Stem Cell Transplantation for Relapsed Multiple Myeloma". Based on the need to improve outcomes post second autologous stem cell transplant (ASCT) for multiple myeloma (MM) and the benefits seen of maintenance treatment following initial ASCT, the natural next step is to evaluate maintenance/continuation therapy following second ASCT. Pomalidomide is acti...

What is the current status of trial NCT03030261?

This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 25 participants. The study started on 2017-11-22. Estimated completion is 2027-09-26.

What conditions does trial NCT03030261 study?

This clinical trial studies the following conditions: Multiple Myeloma in Relapse.

What interventions are being tested in trial NCT03030261?

The interventions under investigation include: Dexamethasone (DRUG), Pomalidomide (DRUG), Elotuzumab (DRUG).

Who is sponsoring clinical trial NCT03030261?

This trial is sponsored by Washington University School of Medicine, which has 1,502 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03030261 being conducted?

This trial has 3 study locations across Colorado, Missouri, Ontario. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Multiple Myeloma in Relapse

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Multiple Myeloma in Relapse

All registered trials for this condition

Colorado

All trials with a study site in Colorado

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.